Equities research analysts at StockNews.com assumed coverage on shares of XBiotech (NASDAQ:XBIT – Get Rating) in a research note issued to investors on Tuesday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.
XBiotech Stock Down 1.8 %
Shares of NASDAQ XBIT opened at $3.29 on Tuesday. The firm has a market cap of $100.15 million, a PE ratio of -2.76 and a beta of 1.22. XBiotech has a 12-month low of $3.00 and a 12-month high of $6.96. The company’s fifty day simple moving average is $3.41 and its 200 day simple moving average is $3.54.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently bought and sold shares of XBIT. Millennium Management LLC raised its holdings in shares of XBiotech by 1,602.0% in the second quarter. Millennium Management LLC now owns 284,679 shares of the biopharmaceutical company’s stock valued at $1,603,000 after purchasing an additional 267,953 shares during the last quarter. Renaissance Technologies LLC purchased a new stake in XBiotech during the second quarter worth about $443,000. Credit Suisse AG increased its holdings in XBiotech by 45.1% during the second quarter. Credit Suisse AG now owns 226,147 shares of the biopharmaceutical company’s stock worth $1,273,000 after buying an additional 70,294 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in XBiotech by 50.8% during the first quarter. Dimensional Fund Advisors LP now owns 153,918 shares of the biopharmaceutical company’s stock worth $1,330,000 after buying an additional 51,872 shares during the last quarter. Finally, Citadel Advisors LLC increased its holdings in XBiotech by 96.0% during the second quarter. Citadel Advisors LLC now owns 80,884 shares of the biopharmaceutical company’s stock worth $455,000 after buying an additional 39,615 shares during the last quarter. 10.06% of the stock is owned by institutional investors.
XBiotech, Inc is a biopharmaceutical company, which engages in the development and commercialization of therapeutic antibodies. Its product pipeline includes oncology, infectious diseases, dermatology and inflammatory disorders. The company was founded by John Simard on March 22, 2005 and is headquartered in Austin, TX.
- Get a free copy of the StockNews.com research report on XBiotech (XBIT)
- Is the Electric Vehicle Movement Losing Steam?
- 3 High-Yield Banks Insiders Are Buying
- Will ChatGPT Be the Final Nail in the Coffin for Chegg?
- Is the Market Reacting Too Negatively to Pinterest Earnings?
- More Analysts Should See Energizer Holdings As A Buy: Here Is Why
Receive News & Ratings for XBiotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XBiotech and related companies with MarketBeat.com's FREE daily email newsletter.